Hypertriglyceridemia

Noncommunicable diseases like type 2 diabetes and cardiovascular disease cause more deaths worldwide than any other conditions, with a growing impact especially in low- and middle-income countries. Cardiovascular disease (CVD) is a leading cause of death globally, and its prevalence is rising despite awareness efforts. Diet and nutrition are important factors influencing these diseases, and this research explores the role of a traditional Chinese medicine nutritional drink in supporting cardiovascular health. The study evaluates the effects of the "Perfect Heartio" drink, a nutritional supplement made from diluted herbal extracts traditionally used in Chinese medicine. Participants will consume 15 grams of the drink twice daily for 12 weeks while their compliance is monitored. This intervention is being studied to assess its potential in improving heart and blood vessel function by measuring various cardiovascular health indicators. Participants will be assessed at the start and at weeks 4, 8, and 12 for lipid profiles, heart inflammation, heart injury, and heart remodeling. Quality of life and self-perceived health status will also be evaluated over these timepoints. The study includes healthy adults aged 18 and above who agree to follow the intervention plan and attend follow-up visits. Monitoring throughout the study will help researchers understand the drink's impact on cardiovascular health markers over the 12-week period.

Researchers are evaluating an AI-assisted digital health tool called the "Smart family doctor" to improve control of hypertension, diabetes, and dyslipidemia in adults who have undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). This study uses a randomized controlled design involving about 536 participants across 5-10 hospitals. Participants must be adults aged 18 or older with a history of CABG or PCI and the specified conditions. Participants in the experimental group will use the AI-assisted "Smart family doctor" app that provides personalized health education, targeted guidance on managing blood pressure, blood sugar, medication adherence, exercise, and smoking cessation. They will also receive tailored reminders and can report self-measured health data for feedback. Both groups receive weekly 3-hour health management guidance from health managers, and participants will wear a smart band daily for health data collection during the 6-month study period. Throughout the study, participants will be assessed for control rates of hypertension, diabetes, and hyperlipidemia at 6 months. Additional measures include blood pressure, cholesterol levels, blood glucose, physical activity, quality of life, psychological status, and cognitive function. The study monitors health data continuously via smart bands and collects self-reports and clinical assessments to evaluate the intervention's impact over the 6 months.

Researchers are studying a medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C) in people with high cholesterol. This trial aims to learn if enlicitide given with rosuvastatin, a standard cholesterol-lowering treatment, works better than a placebo. The study is a phase 3, randomized, double-blind, placebo-controlled trial evaluating the combination's effect on LDL-C levels in adults with hyperlipidemia. Participants will be assigned to one of four groups: enlicitide with a placebo matching rosuvastatin, enlicitide with rosuvastatin, rosuvastatin with a placebo matching enlicitide, or placebos for both drugs. All treatments are taken orally once daily for up to 12 weeks. This setup helps researchers compare the effects of enlicitide alone, rosuvastatin alone, their combination, and placebo. During the study, participants will have their LDL-C levels measured at baseline and at weeks 8 and 12. Researchers will also monitor apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), and adverse events. The main outcome is the percent change in LDL-C at week 8. Safety and tolerability are assessed throughout the treatment and up to about 20 weeks. The total participation duration is up to 12 weeks of treatment with follow-up monitoring.

Researchers are evaluating the effects of Diaberine, a berberine-based nutraceutical, on blood sugar regulation and metabolism in adults with metabolism disorder. This randomized, triple-blind, placebo-controlled trial will study 80 participants aged 18 to 70 over 24 weeks to assess how well this dietary supplement may aid in these health areas. Participants will be randomly assigned to one of two groups. One group will take Diaberine capsules containing Vitamin B12, berberine, magnesium citrate, cinnamon bark extract, chromium, and other ingredients three times daily, 15 minutes before meals. The other group will take placebo capsules with similar appearance but without the active ingredients. Both treatments will continue for 24 weeks with regular monitoring. During the study, participants will have their blood sugar regulation and metabolism measured at baseline, week 12, and week 24. Additionally, quality of life and weight changes will be tracked at multiple points throughout the 24 weeks. Participants will be monitored through questionnaires, blood tests, and weight assessments to evaluate the supplement's effects and tolerance over time.

Researchers are studying the effects of MAR001 on adults with high triglycerides and remnant cholesterol. This phase 2, randomized, double-blind, placebo-controlled trial aims to compare MAR001 with a placebo to see how it changes triglyceride levels after eating a mixed meal. The study focuses on the postprandial (after eating) state in adults aged 18 to 75 years with elevated triglycerides and remnant cholesterol. Participants receive either MAR001 or a matching placebo through subcutaneous injections. The treatment period lasts 12 weeks, during which researchers measure changes in triglycerides and remnant cholesterol levels after a mixed meal. The study uses a quadruple-blind design, meaning participants, care providers, investigators, and outcomes assessors do not know who receives MAR001 or placebo. During the study, participants will have fasting triglyceride tests at screening and regular assessments throughout the 12 weeks. Researchers will track the area under the curve and peak plasma concentrations of triglycerides and remnant cholesterol after meals to evaluate treatment effects. Participants must maintain stable diets and medication regimens during the trial. Safety and adherence will be monitored with ongoing assessments to understand the impact of MAR001 compared to placebo.

Researchers are evaluating the safety and tolerability of multiple subcutaneous injections of JMT202 in Chinese adults with hypertriglyceridemia. This study is a Phase 1b/2a randomized, double-blind, placebo-controlled trial aimed at assessing how participants respond to this investigational treatment, including its effects on triglyceride levels and overall health markers. Participants will receive either JMT202 injections or placebo injections according to the study protocol. The study involves multiple doses administered under medical supervision. Some participants in each dose group will also undergo MRI-PDFF scans to assess fat content. Throughout the trial, participants are expected to maintain their usual diet and exercise habits while avoiding alcohol and strenuous exercise before visits. During the study, participants will undergo regular safety assessments including monitoring for treatment-emergent adverse events, vital signs, physical exams, laboratory tests, electrocardiograms, and injection site reactions from Day 1 to Day 99. The trial period includes careful observation of health changes and adherence to stable lipid-lowering treatments. The total duration of participant involvement spans from screening through approximately three months of follow-up after treatment begins.

Researchers are evaluating the appropriate dosage of HRS-1301 in adults with dyslipidemia, a condition involving abnormal lipid levels in the blood. This phase II trial aims to assess both the effectiveness and safety of HRS-1301 after 12 weeks of treatment. The study is led by Shandong Suncadia Medicine Co., Ltd. and involves participants with varying degrees of cardiovascular risk and cholesterol levels. Participants will be randomly assigned to one of several groups receiving different oral doses of HRS-1301 or a placebo. The study is double-blind and placebo-controlled, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. Treatment lasts 12 weeks, with doses ranging across multiple groups to determine the most suitable amount. During the trial, participants will have their cholesterol levels and related markers regularly monitored to measure changes from baseline. The primary outcome focuses on the percentage change in LDL cholesterol after 12 weeks. Secondary outcomes include changes in total cholesterol, HDL, triglycerides, other lipid markers, and inflammation levels. Safety will be monitored by recording adverse events over approximately six months. Participants will attend scheduled visits for assessments throughout the study.

Researchers are evaluating CTX310, a lipid nanoparticle formulation of CRISPR-Guide RNA-Cas9 nuclease, in adults aged 18 to 75 with dyslipidemias that do not respond to available treatments. This phase 1, open-label, multicenter trial aims to assess the safety and tolerability of this in vivo gene editing approach targeting the ANGPTL3 gene. The study is sponsored by CRISPR Therapeutics AG and explores a new treatment option for difficult-to-treat lipid disorders.

Researchers are evaluating how the body processes HRS-1301 tablets in adults with different levels of kidney function compared to healthy adults. The goal is to understand how kidney impairment affects the medicine's behavior in the body and to develop dosing recommendations for patients with kidney problems. This is a phase 1 clinical trial sponsored by Shandong Suncadia Medicine Co., Ltd. Participants will receive a single oral dose of HRS-1301 tablets. The study includes groups with mild, moderate, and severe kidney impairment as well as healthy subjects. The trial is open-label, meaning both researchers and participants know the treatment being given. The treatment period lasts up to 8 days post-dose to observe the drug's effects. During the study, participants will undergo blood and urine tests to measure drug levels and how the body clears the medicine over time. Researchers will track maximum drug concentration, exposure over time, elimination half-life, and safety through adverse event monitoring. These assessments occur from dosing up to 8 days later. The total participation duration varies but includes close monitoring of drug behavior and safety.

Researchers are evaluating the safety and effectiveness of solbinsiran in lowering triglyceride levels and other lipid measures in adults with severe hypertriglyceridemia. This phase 2 study compares solbinsiran to a placebo and aims to better understand how this treatment might help people with this condition. The trial is sponsored by Eli Lilly and Company and focuses on participants with very high fasting triglyceride levels. Participants will be randomly assigned to receive either solbinsiran or a placebo through two subcutaneous injections. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo. The main treatment period includes monitoring changes in triglycerides and other lipid markers over 16 to 24 weeks. During the study, participants will have fasting triglyceride levels measured at baseline and during follow-up visits. Researchers will also assess changes in other blood lipids such as ANGPTL3, VLDL cholesterol, and non-HDL cholesterol at 24 weeks. Pharmacokinetic testing will measure how the body processes solbinsiran after dosing. The study runs from December 2025 to August 2027, with safety and efficacy monitored throughout.